Assessment of the Diagnostic Value of Sentinel Lymph Node Mapping with Blue Dye (Blue Methylene) with Complete Lymph Node Dissection for Endometrial Cancer Staging Surgery (a Multicenter, Prospective, Cross-Sectional Study)

In gynecological cancers, sentinel lymph node (SLN) mapping has been proposed as an alternative to complete lymph node dissection. The goal of this study was to determine sentinel lymph node mapping's sensitivity, specificity, NPV, and PPV versus gold standard surgery (complete lymph node dissection) in patients with metastatic illness. A total of ۲۶ patients were prospectively enrolled from spring ۲۰۲۱ to winter ۲۰۲۲. Sentinel lymph node mapping with complete pelvic lymph node dissection was done in all of them, and para-aortic lymphadenectomy was detected in ۱۱ (۴۳.۳۳%) patients. At least one sentinel lymph node was successfully mapped in ۲۲ (۸۴.۶%) patients. Three patients (۱۱.۵%) had positive lymph nodes, with an ۸۵.۷% sensitivity (۹۵ percent CI) to detect node positive illness, a specificity of ۷۴.۹۳%, an NPV of ۹۹.۶ (۹۹.۵ CI), and a PPV of ۵.۹% calculated. There were no serious adverse effects due to blue dye. The accuracy rate of sentinel lymph node mapping by methylene blue was ۷۵.۱%.